imatinib mesylate has been researched along with Diabetic Angiopathies in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, TJ; Candido, R; Cao, Z; Cooper, ME; Jandeleit-Dahm, KA; Lassila, M; Thallas, V | 1 |
1 other study(ies) available for imatinib mesylate and Diabetic Angiopathies
| Article | Year |
|---|---|
Imatinib attenuates diabetes-associated atherosclerosis.
Topics: Animals; Aorta; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Benzamides; Cytokines; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Drug Evaluation, Preclinical; Enzyme Inhibitors; Genes, abl; Genes, sis; Glycated Hemoglobin; Imatinib Mesylate; Intercellular Signaling Peptides and Proteins; Lipids; Male; Mice; Mice, Knockout; Organometallic Compounds; Peptides; Piperazines; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-sis; Pyrimidines; Random Allocation; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; Streptozocin; Systole; Vascular Cell Adhesion Molecule-1 | 2004 |